Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Clathrin heavy chain 1 (CLTC)
- Target
- CLTC
- Molecular classification
- Other (coat protein, structural protein), Vesicular transport protein, Cytoskeletal-associated protein
01
Overview
Clathrin heavy chain 1 is a large protein found on the cytoplasmic face of intracellular organelles, particularly clathrin-coated vesicles and pits. These vesicles are crucial for the internalization and trafficking of receptors, endocytosis of macromolecules, and maintenance of cellular homeostasis. The basic clathrin triskelion structure is formed by three heavy chains and three light chains, assembling into lattices that curve to generate vesicle coats. Clathrin heavy chain also interacts with several adaptor proteins and is essential in autophagy and mitosis. Pathologically, chromosomal rearrangements that fuse CLTC with receptor tyrosine kinases, such as ALK, can drive constitutive kinase activation, contributing to malignancy in a subset of lymphomas and other tumors
- Other names
- Clathrin heavy chainCLH17CLTCL2KIAA0034CLH-17HcClathrin heavy chain on chromosome 17CHCCHC17clathrin, heavy polypeptide (Hc)clathrin, heavy polypeptide-like 2MRD56
02
Mechanism of action
In cases of CLTC–ALK fusion, therapeutic mechanism involves **inhibition of the ALK kinase activity**
03
Biological functions
Vesicle formationReceptor-mediated endocytosisIntracellular traffickingAutophagyMitotic spindle formation and chromosome segregation
04
Disease associations
Cancer (oncogenic fusions, e.g. CLTC–ALK, with constitutive activation in certain lymphomas)Neurodegenerative disease (general involvement in vesicle trafficking)Other (possible implications in infection and membrane trafficking disorders)
05
Safety considerations
Direct targeting of clathrin function could disrupt fundamental cell viability and trafficking.Potential neurotoxicity and cell death if endocytosis and receptor trafficking are globally inhibited
06
Interacting drugs
crizotinib
1 more in the full profile.
07
Biomarkers
Presence of CLTC–ALK fusion as a diagnostic and prognostic biomarker in select lymphomas and cancersCLTC abnormalities can indicate dysregulated membrane trafficking in experimental models.
Beyond the preview
Go deeper on Clathrin heavy chain 1 (CLTC).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clathrin heavy chain 1 (CLTC).